Trials / Completed
CompletedNCT06796868
A Study to Evaluate Efficacy and Safety of GW117 Tablets in Major Depressive Disorder
A Multicenter, Randomized , Double-blind, Parallel, Placebo-controlled Design Clinical Trial of GW117 Tablets
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 280 (actual)
- Sponsor
- Beijing Greatway Pharmaceutical Technology Co.,Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The study aims to evaluate the efficacy and safety of GW117 Tablets compared to placebo in adults participants with MDD over a period of 8 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GW117 Tablets | GW117 Tablets 20mg orally once a day |
| DRUG | GW117 Tablets | GW117 Tablets 20mg\*2 orally once a day |
| DRUG | GW117 Tablets | GW117 Tablets 20mg\*3 orally once a day |
| DRUG | Placebo | placebo orally once a day |
Timeline
- Start date
- 2022-07-07
- Primary completion
- 2023-09-28
- Completion
- 2023-10-12
- First posted
- 2025-01-28
- Last updated
- 2025-04-23
Locations
17 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06796868. Inclusion in this directory is not an endorsement.